Radiopharmaceuticals for palliation of painful osseous metastases

Annu Navani, Howard Smith, Scott M Fishman

Research output: Contribution to journalArticlepeer-review


Bone pain secondary to metastases may develop in more than half of patients with metastatic cancer. The treatment of metastatic osseous pain usually begins with oral analgesics following the WHO-ladder followed by external beam radiotherapy, ablative nerve blocks and implantable devices. Despite aggressive interventions, pain control seems challenging in this population. Treatment strategies including bisphosphonates, mitoxantrone and hormonal therapy have recently come into light. In some cases of osseous metastasis, radiopharmaceuticals may prove to be beneficial as an additional non-invasive therapy. This discussion will review different radiopharmaceutical agents available today including Strontium-89 chloride, Phosphorus-32 orthophosphate and Samarium-153 lexidronam and their clinical considerations.

Original languageEnglish (US)
Pages (from-to)25-36
Number of pages12
JournalJournal of Cancer Pain and Symptom Palliation
Issue number2
StatePublished - Dec 15 2005


  • Bone
  • Metastases
  • Pain
  • Palliation
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology


Dive into the research topics of 'Radiopharmaceuticals for palliation of painful osseous metastases'. Together they form a unique fingerprint.

Cite this